Home / USA / Healthcare and Pharmaceutical Law
HEALTHCARE · PATENT LITIGATIONGSK and Moderna Settle Patent Dispute Over COVID-19 and RSV Vaccines
GSK and Moderna settled patent litigation involving Moderna’s COVID-19 vaccines and RSV shot. The companies agreed to cross-license patents in infectious disease and said no payments are required under those licenses.
WASHINGTON, November 6, 2026: GSK and Moderna settled patent litigation involving Moderna’s COVID-19 vaccines and RSV shot. The companies agreed to cross-license patents in infectious disease and said no payments are required under those licenses.
GSK and Moderna have settled lawsuits over patents related to Moderna’s COVID-19 vaccines Spikevax and mNEXSPIKE and its RSV vaccine mResvia, the companies said Friday, according to Reuters.
What the settlement provides
Moderna said the settlement was reached on October 28 and covers patent litigation in the United States and Europe. The companies granted each other patent cross-licenses in the field of infectious disease and are not required to make payments in connection with those licenses, Reuters reported.
The companies also asked a federal court in Delaware to dismiss GSK’s U.S. infringement claims with prejudice. That legal term means the claims cannot simply be brought again in the same form. The settlement is a negotiated resolution, not a court finding that Moderna infringed GSK patents or that GSK’s claims were proven.
Why the patents mattered
GSK sued Moderna in 2024 over lipid-nanoparticle technology used to carry fragile mRNA into the body. Lipid nanoparticles help deliver genetic instructions to cells and are an important part of some mRNA vaccines. Patent rights around this technology have become a major issue as drugmakers protect research and manufacturing methods.
The settlement covers the disputes between GSK and Moderna described in the companies’ announcement. It does not resolve every mRNA patent case. Reuters reported that GSK has a separate lawsuit against Pfizer and BioNTech over their COVID-19 vaccine that remains ongoing.
What it means
Resolving the litigation can reduce legal uncertainty for both companies. It does not change the clinical evidence, FDA status or safety profile of any vaccine. For investors, the agreement illustrates how intellectual-property disputes can shape biotechnology economics.
Editorial note: A settlement is not a judicial finding of infringement or liability. The cross-licenses and court dismissal request are described as reported by Reuters.
Related coverage: Latest U.S. news · Business and finance news